Clearmind Medici Stock Price, News & Analysis

Clearmind Medicine (NASDAQ: CMND) has received Institutional Review Board (IRB) approval from Hadassah Medical Center for its Phase 1/2a clinical trial of CMND-100, a MEAI-based oral drug candidate for Alcohol Use Disorder (AUD). This approval follows FDA IND clearance and enables patient enrollment at the Jerusalem-based facility.

The multinational, multi-center trial will be conducted at several prestigious institutions, including Yale School of Medicine, Johns Hopkins University, and Tel Aviv Sourasky Medical Center. The study aims to evaluate CMND-100's safety, tolerability, pharmacokinetic profile, and preliminary efficacy in reducing alcohol cravings and consumption in AUD patients.

The trial addresses a significant global health issue, as AUD accounts for 4.7% of worldwide deaths according to WHO data.

Clearmind Medicine (Nasdaq: CMND) has filed an international patent application under the Patent Cooperation Treaty (PCT) for a novel combination therapy using MEAI and Palmitoylethanolamide (PEA). The therapy targets obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).

The company is developing this treatment in collaboration with SciSparc Ltd. (Nasdaq: SPRC). The therapy aims to address significant global health challenges, with obesity affecting over 890 million people worldwide and non-alcoholic fatty liver disease (NAFLD) impacting more than 30% of the global adult population.

Clearmind Medicine (Nasdaq: CMND) has successfully completed site initiation at Tel Aviv Sourasky Medical Center (TASMC) for its Phase I/IIa clinical trial of CMND-100, a novel oral drug candidate for Alcohol Use Disorder (AUD). The trial is being conducted across multiple prestigious institutions, including Yale School of Medicine, Johns Hopkins University, and Israeli medical centers.

The study aims to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, while also assessing early efficacy signals in reducing alcohol cravings and consumption. The drug candidate utilizes 5-methoxy-2-aminoindane (MEAI) to potentially treat AUD, which currently affects millions globally and causes 2.6 million deaths annually.

Clearmind Medicine (Nasdaq: CMND) has expanded its Phase I/IIa clinical trial for CMND-100, its MEAI-based oral treatment for Alcohol Use Disorder (AUD). The company has activated a new clinical site at Johns Hopkins University School of Medicine and enrolled its first participant there.

The trial aims to evaluate safety, tolerability, and pharmacokinetic profile of CMND-100, while also assessing preliminary efficacy in reducing alcohol cravings and consumption. This expansion follows the recent enrollment of the first participant at Yale School of Medicine, demonstrating momentum in the multinational, multicenter study.

Clearmind Medicine (NASDAQ: CMND) has received Institutional Review Board (IRB) approval from Tel Aviv Sourasky Medical Center (TASMC) for its ongoing Phase 1/2a clinical trial of CMND-100, a MEAI-based oral drug candidate for Alcohol Use Disorder (AUD).

The trial, which recently began dosing its first participant, will be conducted at several prestigious institutions including Yale School of Medicine, Johns Hopkins University, and Hadassah-University Medical Center. At TASMC, the study will be led by Dr. David Zeltser, Director of Emergency Medicine Department.

The multinational, multi-center study aims to evaluate CMND-100's safety, tolerability, and pharmacokinetic profile, while assessing its preliminary efficacy in reducing alcohol cravings and consumption in AUD patients. This development addresses a significant global health issue, as AUD accounts for 4.7% of worldwide deaths according to WHO.

Clearmind Medicine (Nasdaq: CMND) has achieved a significant milestone by dosing the first participant with CMND-100, its proprietary MEAI-based oral drug candidate, in a Phase I/IIa clinical trial for Alcohol Use Disorder (AUD). This marks the first human administration of the company's novel treatment in a clinical setting.

The multinational, multicenter trial is being conducted at prestigious institutions including Yale School of Medicine, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah-University Medical Center. The study aims to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, while also assessing its preliminary efficacy in reducing alcohol cravings and consumption.

This development follows the company's June 5, 2025 announcement of the first participant enrollment. The trial will include both single- and multiple-dose studies to establish safety and optimal dosing parameters.

Clearmind Medicine (Nasdaq: CMND) announced the expansion of its Phase I/IIa clinical trial for CMND-100, a MEAI-based oral drug candidate targeting Alcohol Use Disorder (AUD). The company has added Hadassah-University Medical Center in Jerusalem as a new trial site, joining prestigious institutions including Yale School of Medicine, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and IMCA.

The trial aims to evaluate safety, tolerability, and pharmacokinetics of CMND-100, while exploring its potential to reduce alcohol cravings. The expansion targets the global AUD market affecting over 280 million people, representing a multibillion-dollar opportunity given current limited treatment options.

Clearmind Medicine (NASDAQ: CMND) has announced the enrollment of its first patient in a Phase I/IIa clinical trial for CMND-100, their MEAI-based oral drug candidate for treating Alcohol Use Disorder (AUD). The trial, conducted at Yale School of Medicine's Department of Psychiatry and Johns Hopkins University, will evaluate the drug's safety, tolerability, and pharmacokinetic profile.

The study targets individuals aged 18-60 who either report heavy binge drinking or are diagnosed with AUD. The U.S. substance use disorder treatment market, valued at $35.1 billion in 2021, is projected to reach $60.2 billion by 2029. The company aims to address limitations in current AUD treatments, which have shown limited effectiveness and adverse side effects.

Clearmind Medicine (Nasdaq: CMND) has partnered with a leading government affairs consulting firm to advance psychedelic-based treatments in the healthcare sector. The collaboration aims to navigate regulatory landscapes and promote acceptance of psychedelic therapeutics among U.S. policymakers.

The company's lead candidate, CMND-100, is currently undergoing Phase I/IIa clinical trials for Alcohol Use Disorder (AUD) at Yale School of Medicine and Johns Hopkins University. The partnership focuses on educating policymakers about psychedelics' therapeutic potential, particularly for treating conditions like PTSD and mental health disorders, while supporting the development of science-based regulatory frameworks.